Anthem Biosciences Ltd
NSE: ANTHEM · Biotechnology · sector
₹822.25NSE close 2026-10-26
Key numbers
Market cap₹46,324 cr
Price₹822.25
52w high / low₹978 / ₹579
P/E80.2xSector median 40.2x
P/B15.2xSector median 1.4x
Book value₹54.0
Dividend yield–Sector median 2.11%
ROE18.9%Sector median -0.0%
ROCE25.5%Sector median 3.3%
OPM38.4%Sector median 31.3%
Debt / equity0.02xSector median 0.01x
EV/EBITDA59.1xSector median 34.1x
Interest cover127.8x
Current ratio5.54x
Sales growth 3y–Sector median -26.4%
Profit growth 3y–Sector median -43.0%
PEG–
Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 6 companies in Biotechnology (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹940 cr vs borrowings ₹51 cr (FY26): cash is higher (net cash).
- Operating profit covered interest 127.8x in the last 12 months.
- Promoter holding fell by 3.29 percentage points in a year, to 71.40% (2026-09-30).
- Other income was 27% of net profit in the last 12 months.
- No dividend in the last 1 financial years.
- Price ₹822.25 on 2026-10-26: -15.9% from the 52-week high, +42.0% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹942.95 · low ₹599.30
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|
| Revenue | 540 | 550 | 423 | 611 | 418 |
| EBITDA | 191 | 218 | 132 | 268 | 151 |
| OPM % | 35.4% | 39.6% | 31.2% | 43.9% | 36.0% |
| Other income | 23 | 48 | 34 | 51 | 25 |
| Net profit | 136 | 173 | 93 | 190 | 120 |
| EPS (₹) | 2.43 | 3.09 | 1.65 | 3.38 | 2.13 |
| Revenue YoY | -22.6% | ||||
| Profit YoY | -11.7% |
Consolidated figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY26 | TTM |
|---|---|---|
| Revenue | 2,124 | 2,002 |
| EBITDA | 809 | 768 |
| Net profit | 592 | 576 |
| EPS (₹) | 10.55 | 10.25 |
| Dividend / share (₹) | – |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | – | – | – |
| Net profit | – | – | – |
| EPS | – | – | – |
| Share price | – | – (2y) | +8.5% |
Balance sheet
| ₹ cr | FY26 |
|---|---|
| Shareholders' equity | 3,043 |
| Borrowings | 51 |
| Cash & equivalents | 940 |
| Total assets | 3,429 |
| Fixed assets | 780 |
| Capital work in progress | 264 |
| Investments | 342 |
| Receivables | 591 |
| Inventory | 125 |
| Payables | 75 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY26 |
|---|---|
| Cash from operations | 844 |
| Cash from investing | -702 |
| Cash from financing | -40 |
| Capex | 211 |
| Free cash flow | 633 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY26 |
|---|---|
| ROE % | 19.5% |
| ROCE % | 26.9% |
| Debtor days | 101 |
| Inventory days | 56 |
| Payable days | 34 |
| Cash conversion cycle (days) | 123 |
| Working capital days | 254 |
Shareholding
| Holder | % (2026-09-30) |
|---|---|
| Promoters | 71.40% |
| FIIs | 3.79% |
| DIIs | 12.10% |
| of which Mutual funds | 9.25% |
| of which Insurance | 1.72% |
| Government | 0.00% |
| Public (non-institutions) | 12.70% |
| Quarter | Jul 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|
| Promoters % | 74.69% | 74.69% | 74.69% | 74.68% | 71.42% | 71.40% |
| Promoter group | % |
|---|---|
| Ajay Bhardwaj | 42.39% |
| Ishaan Bhardwaj | 10.12% |
| Ganesh Sambasivam | 8.10% |
| K C Ravindra | 7.75% |
| S Vijayalakshmi | 1.01% |
| KEERTHI TRUST(Trustee is K C RAVINDRA) | 1.01% |
| SWARA TRUST(Trustee is K C RAVINDRA) | 1.01% |
| Krithika Ganesh | 0.00% |
| Aruna Ganesh | 0.00% |
| Arti Bhardwaj | 0.00% |
| Madhavi Jayanti | 0.00% |
| Jyotsna Bhardwaj | 0.00% |
| Aditya Narian Capoor | 0.00% |
| Archana Mathur | 0.00% |
| Sambasivam Hariharan | 0.00% |
| Public holders above 1% | % |
|---|---|
| Portsmouth Technologies LLC | 2.73% |
| Malay Jiban Barua | 2.26% |
| Rupesh Narharrao Kinekar | 2.26% |
| Satish S Sharma | 2.26% |
| HDFC Mutual Fund - HDFC Business Cycle Fund | 1.90% |
| SBI MNC Fund | 1.75% |
| Axis Elss TAX Saver Fund | 1.36% |
1,76,209 shareholders. Pledged: – of promoter shares.
Peers in Biotechnology
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| ANTHEM | ₹46,324 cr | 80.2x | 15.2x | 18.9% | 25.5% | 38.4% | – | – |
| ADVENZYMES | ₹2,823 cr | 17.0x | 1.7x | 10.9% | 14.1% | 31.3% | +11.3% | 2.11% |
| CCME | ₹43 cr | 58.0x | 1.1x | -3.5% | -2.1% | – | – | – |
| VIVOBIOT | ₹29 cr | 3.6x | 0.3x | -3.3% | 5.8% | 37.0% | +1.1% | – |
| SHREEGANES | ₹18 cr | 22.5x | 0.3x | -0.6% | -0.6% | -35.1% | -57.0% | – |
| GVBL | ₹12 cr | 329.9x | 3.1x | 0.5% | 0.8% | 15.6% | -53.8% | – |
Business segments (FY26)
| Segment | Revenue | Share | EBIT | Margin |
|---|---|---|---|---|
| CRDMO | ₹1,773 cr | 83.5% | ₹1,133 cr | 63.9% |
| Speciality Ingredients | ₹352 cr | 16.5% | ₹179 cr | 50.9% |
Dividends & corporate actions
| Ex-date | Action | Detail |
|---|---|---|
| 2026-06-25 | Dividend | Dividend - Rs 2 Per Share |
Documents
- Annual report FY26
- Annual report FY26
- Announcements NSE filings
- BRSR FY26
- Latest results (data file) XBRL
- Announcements BSE filings
Links go to the original files on the exchange website.
About the company
- Contract research , development , and manufacturing services: Provide scientific solutions through integrated research, development and manufacturing
| Sector | Healthcare |
| Industry | Biotechnology |
| Sub-industry | Biotechnology |
| Symbol | ANTHEM |
| BSE code | 544449 |
| ISIN | INE0CZ201020 |
| Face value | ₹2.0 |
| Incorporated | 2006-06-13 |
| Website | https://anthembio.com |
| Plants (India / abroad) | 3 / 0 |
From the company's filings (BRSR FY26).
Data built 2026-10-22 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.